Role of Transhepatic Arterial Radioembolization in Metastatic Colorectal Cancer

Bargellini, Irene; Bozzi, Elena; Lorenzoni, Giulia; Boni, Giuseppe; Bianchi, Francesca; Traino, Claudio; Masi, Gianluca; Cioni, Roberto; Crocetti, Laura

doi:10.1007/s00270-022-03268-y

Cited by 5 publications

(2 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Alternative treatments to SRT include radio frequency [ 53 , 54 ], electroporation [ 38 ], laser interstitial thermal therapy [ 55 ], and others [ 56 , 57 ]. The choice of DLT depends on the patient’s medical condition, tumor location, center expertise, and multidisciplinary consensus.…”

Section: Definitive Local Therapies In Omdmentioning

confidence: 99%

Oligo-Metastatic Cancers: Putative Biomarkers, Emerging Challenges and New Perspectives

Ottaiano

Santorsola

Circelli³

et al. 2023

Cancers

View full text Add to dashboard Cite

Some cancer patients display a less aggressive form of metastatic disease, characterized by a low tumor burden and involving a smaller number of sites, which is referred to as “oligometastatic disease” (OMD). This review discusses new biomarkers, as well as methodological challenges and perspectives characterizing OMD. Recent studies have revealed that specific microRNA profiles, chromosome patterns, driver gene mutations (ERBB2, PBRM1, SETD2, KRAS, PIK3CA, SMAD4), polymorphisms (TCF7L2), and levels of immune cell infiltration into metastases, depending on the tumor type, are associated with an oligometastatic behavior. This suggests that OMD could be a distinct disease with specific biological and molecular characteristics. Therefore, the heterogeneity of initial tumor burden and inclusion of OMD patients in clinical trials pose a crucial methodological question that requires responses in the near future. Additionally, a solid understanding of the molecular and biological features of OMD will be necessary to support and complete the clinical staging systems, enabling a better distinction of metastatic behavior and tailored treatments.

show abstract

Section: Definitive Local Therapies In Omdmentioning

confidence: 99%

Oligo-Metastatic Cancers: Putative Biomarkers, Emerging Challenges and New Perspectives

Ottaiano

Santorsola

Circelli³

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…TACE) if systemic therapies are not feasible or as an adjunct to systemic therapies and in locally limited intrahepatic cholangiocarcinoma in second-line therapy for selected patients [15][16][17][18]. Furthermore, SIRT is a long-established concept for treating liver metastasis of different primarily extrahepatic tumors [19][20][21][22].…”

Section: Introductionmentioning

confidence: 99%

Current Developments of Selective Internal Radiotherapy (SIRT) in Germany: A Systematic Analysis of Indication and Hospital Mortality between 2012 and 2019

Mertens

Essing

Minko

et al. 2022

Preprint

View full text Add to dashboard Cite

Background Selective Internal Radiotherapy (SIRT) is a minimal invasive tumor therapy for hepatocellular carcinoma (HCC), biliary tract cancer (BTC), and liver metastasis of extrahepatic tumors. Comprehensive data on past and current trends of SIRT as well as outcome parameters such as in-hospital mortality and adverse events in Germany are missing. Methods We evaluated current clinical developments and outcomes of SIRT in Germany based on standardized hospital discharge data, provided by the German Federal Statistical Office from 2012 to 2019. Results A total of 11,014 SIRT procedures were included in the analysis. Reflecting the current guideline, the most common indication was hepatic metastases (54.3%; HCC: 39.7%; BTC: 6%) with a trend in favor of HCC and BTC over time. Most SIRTs were performed with yttrium-90 (99.6%) but the proportion of holmium-166 SIRTs increased in recent years. Mean length of hospital stay for ⁹⁰Y based SIRTs was 3.67 ± 2 days and for 166Ho based SIRTs 2.9 ± 1.3 days. Overall in-hospital mortality was 0.14%. The mean number of SIRTs/hospital was 22.9 (SD ± 30.4). The 20 highest case volume centers performed 25.6% of all SIRTs. Conclusion Our study gives a detailed insight into indications, patient-related factors, and the incidence of adverse events as well as the overall in-hospital mortality in a large SIRT collective in Germany. SIRT is a safe procedure with low overall in-hospital mortality and a well-definable spectrum of adverse events. We report differences in the regional distribution of performed SIRTs and changes in the indications and used radiopharmaceuticals over the years.

show abstract

Transarterial radioembolization and its impacts on colon cancer treatment and diagnosis

Chandegra,

Prajapati,

Prajapati

2024

Colorectal Cancer

View full text Add to dashboard Cite

Role of Transhepatic Arterial Radioembolization in Metastatic Colorectal Cancer

Cited by 5 publications

References 58 publications

Oligo-Metastatic Cancers: Putative Biomarkers, Emerging Challenges and New Perspectives

Oligo-Metastatic Cancers: Putative Biomarkers, Emerging Challenges and New Perspectives

Current Developments of Selective Internal Radiotherapy (SIRT) in Germany: A Systematic Analysis of Indication and Hospital Mortality between 2012 and 2019

Transarterial radioembolization and its impacts on colon cancer treatment and diagnosis

Contact Info

Product

Resources

About